Claims
- 1. A process for preparing a thioester compound of formula A:
- 2. The process according to claim 1, wherein the oxidation is performed at a temperature from about −10° C. to about 30° C.
- 3. The process according to claim 1, wherein the oxidation is performed for about 2 hours to about 10 hours.
- 4. The process according to claim 1, wherein R1 is methyl; R2 is methoxy; R3 is methyl and R4 is methoxy.
- 5. The process according to claim 1, wherein R1 is methyl; R2 is 2-trifluoroethoxy; R3 is hydrogen and R4 is hydrogen.
- 6. The process according to claim 1, wherein R1 is methoxy; R2 is methoxy; R3 is hydrogen and R4 is difluoromethoxy.
- 7. The process according to claim 1, wherein R1 is methyl; R2 is MeOCH2CH2CH2O; R3 is hydrogen and R4 is hydrogen.
- 8. The process according to claim 1, wherein the oxidizing agent is tert-butyl hydroperoixde in the presence of a catalyst.
- 9. The process according to claim 8, wherein the catalyst is selected from the group consisting of vanadyl bis-acetylacetonate, sodium meta-vanadate and vanadium pentoxide.
- 10. The process according to claim 8, wherein the molar ratio of tert-butyl hydroperoxide to the compound of formula B is in the range of about 1.15 to about 4.5.
- 11. The process according to claim 8, wherein the catalyst is vanadyl bis-acetylacetonate.
- 12. The process according to claim 8, wherein the vanadyl bis-acetylacetonate and the compound of formula B is in the molar ratio of about 0.01 to about 0.6.
- 13. The process according to any one of claims 8-12, wherein the oxidation is performed in an organic solvent.
- 14. The process according to claim 13, wherein the organic solvent is selected from the group consisting of toluene, lower alkanols and ethyl acetate.
- 15. The process according to claim 13, wherein the oxidation is performed in an organic solvent in the presence of water.
- 16. The process according to claim 1, wherein the oxidizing agent is Oxone®.
- 17. The process according to claim 16, wherein the molar ratio between Oxone® and the compound of formula B is from about 1.25-1.6 to about 1.
- 18. The process according to claim 16, wherein the molar ratio between Oxone® and the compound of formula B is from about 1.4-1.6 to about 1.
- 19. The process according to claim 16, wherein the oxidation is performed of an aqueous organic solvent.
- 20. The process according to claim 16, wherein the oxidation is performed in the presence any one or more of acetone and methanol.
- 21. A process according to claim 16, wherein the oxidation is performed in about 5% aqueous methanol.
- 22. The process according to claim 16, wherein the oxidation is performed in a two-phase system selected from (CH2Cl2/H2O) and (ethyl acetate/H2O).
- 23. The process according to claim 16, wherein the oxidation is performed in the presence of phase-transferred catalyst.
- 24. The process according to claim 16, wherein the oxidation is performed in the presence of tert-butyl ammonium bromide.
- 25. Omerprazole substantially free of sulphone by-product prepared as in any one of claims 1, 4, 8 or 16.
- 26. Lansoprazole substantially free of sulphone by-product prepared as in any one of claims 1, 5, 8 or 16.
- 27. Pantoprazole substantially free of sulphone by-product prepared as in any one of claims 1, 6, 8 or 16.
- 28. Rabeprazole substantially free of sulphone by-product prepared as in any one of claims, 1, 7, 8 or 16.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This invention claims the benefit under 35 U.S.C. §1.119(e) of provisional application Serial No. 60/266,162, filed Feb. 2, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60266162 |
Feb 2001 |
US |